Structure–activity relationship and crystallographic studies on 4-hydroxypyrimidine HIF prolyl hydroxylase domain inhibitors
- The 2‐oxoglutarate‐dependent hypoxia inducible factor prolyl hydroxylases (PHDs) are targets for treatment of a variety of diseases including anaemia. One PHD inhibitor is approved for use for the treatment of renal anaemia and others are in late stage clinical trials. The number of reported templates for PHD inhibition is limited. We report structure–activity relationship and crystallographic studies on a promising class of 4‐hydroxypyrimidine‐containing PHD inhibitors.
- Publication status:
- Peer review status:
- Peer reviewed
(Accepted manuscript, 1.0MB)
- Publisher copy:
- Copyright holder:
- Wiley‐VCH Verlag GmbH & Co. KGaA
- Copyright date:
- Rights statement:
- © 2019 Wiley‐VCH Verlag GmbH & Co. KGaA, Weinheim.
- This is the accepted manuscript version of the article. The final version is available online from Wiley at: https://doi.org/10.1002/cmdc.201900557
If you are the owner of this record, you can report an update to it here: Report update to this record